Dexamethasone/ Erector Spinae Plane Block Analgesia in Laparoscopic Cholecystectomy
Primary Purpose
Post Operative Pain
Status
Not yet recruiting
Phase
Phase 2
Locations
Study Type
Interventional
Intervention
Dexamethasone/ Erector Spinae Plane Block
Erector Spinae Plane Block
Sponsored by
About this trial
This is an interventional prevention trial for Post Operative Pain
Eligibility Criteria
Inclusion Criteria:
- Patients undergoing elective LC under general anesthesia, ASA status I-II, aged from 18 to 65 years old of both sex
Exclusion Criteria:
- Contraindications to regional block (coagulopathy, infection at the needle insertion site, or diaphragmatic paralysis)
- Altered conscious level
- Pregnancy
- Body mass index (BMI > 35)
- Advanced hepatic or renal failure
- Chronic opioid consumption
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Arm Type
Active Comparator
Placebo Comparator
Arm Label
Dexamethasone/ Erector Spinae Plane Block
Erector Spinae Plane Block
Arm Description
Patients will receive bilateral Ultrasound-guided Erector Spinae Plane Block with bupivacaine and dexamethasone 15 minutes before skin incision.
Patients will receive bilateral Ultrasound-guided Erector Spinae Plane Block with bupivacaine and one ml of normal saline 15 minutes before skin incision.
Outcomes
Primary Outcome Measures
The intensity of postoperative pain
Assessed by the verbal analog pain scale graded from 0 to 10 (0 = no pain, and 10 = the worst possible pain)
Secondary Outcome Measures
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT05105997
Brief Title
Dexamethasone/ Erector Spinae Plane Block Analgesia in Laparoscopic Cholecystectomy
Official Title
Dexamethasone as a Bupivacaine Adjuvant in Ultrasound-guided Erector Spinae Plane Block for Patients Undergoing Laparoscopic Cholecystectomy: a Randomized Double-blind Study
Study Type
Interventional
2. Study Status
Record Verification Date
September 2022
Overall Recruitment Status
Not yet recruiting
Study Start Date
December 2022 (Anticipated)
Primary Completion Date
July 2023 (Anticipated)
Study Completion Date
July 2023 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Assiut University
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
5. Study Description
Brief Summary
Although considered a minimally invasive procedure, laparoscopic cholecystectomy (LC) frequently results in moderate to severe immediate postoperative pain.
Detailed Description
Although considered a minimally invasive procedure, laparoscopic cholecystectomy (LC) frequently results in moderate to severe immediate postoperative pain. In addition to predominant visceral pain, nearly half of all patients suffer from shoulder pain in the early postoperative period. The most likely reason is sub-diaphragmatic irritation, which is transmitted by the phrenic nerve, causing referred pain in the C4 dermatome. Due to multiple sources of pain, multimodal analgesia approaches have been used in the perioperative period following LC.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Post Operative Pain
7. Study Design
Primary Purpose
Prevention
Study Phase
Phase 2
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
60 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
Dexamethasone/ Erector Spinae Plane Block
Arm Type
Active Comparator
Arm Description
Patients will receive bilateral Ultrasound-guided Erector Spinae Plane Block with bupivacaine and dexamethasone 15 minutes before skin incision.
Arm Title
Erector Spinae Plane Block
Arm Type
Placebo Comparator
Arm Description
Patients will receive bilateral Ultrasound-guided Erector Spinae Plane Block with bupivacaine and one ml of normal saline 15 minutes before skin incision.
Intervention Type
Drug
Intervention Name(s)
Dexamethasone/ Erector Spinae Plane Block
Intervention Description
Patients will receive bilateral Ultrasound-guided Erector Spinae Plane Block with bupivacaine and dexamethasone 15 minutes before skin incision
Intervention Type
Drug
Intervention Name(s)
Erector Spinae Plane Block
Intervention Description
Patients will receive bilateral Ultrasound-guided Erector Spinae Plane Block with bupivacaine and one ml of normal saline 15 minutes before skin incision.
Primary Outcome Measure Information:
Title
The intensity of postoperative pain
Description
Assessed by the verbal analog pain scale graded from 0 to 10 (0 = no pain, and 10 = the worst possible pain)
Time Frame
24 hours after surgery
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Patients undergoing elective LC under general anesthesia, ASA status I-II, aged from 18 to 65 years old of both sex
Exclusion Criteria:
Contraindications to regional block (coagulopathy, infection at the needle insertion site, or diaphragmatic paralysis)
Altered conscious level
Pregnancy
Body mass index (BMI > 35)
Advanced hepatic or renal failure
Chronic opioid consumption
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Seham M Moeen, MD
Phone
01006386324
Ext
02
Email
seham.moeen@aun.edu.eg
First Name & Middle Initial & Last Name or Official Title & Degree
Girgis W Alexan, Msc
Phone
01200379884
Ext
02
Email
welsonnet89@gmail.com
12. IPD Sharing Statement
Learn more about this trial
Dexamethasone/ Erector Spinae Plane Block Analgesia in Laparoscopic Cholecystectomy
We'll reach out to this number within 24 hrs